Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 127, Issue 4, Pages 881-886Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.jid.5700653
Keywords
-
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA069184, P01CA092644] Funding Source: NIH RePORTER
- NCI NIH HHS [CA69184, CA92644] Funding Source: Medline
Ask authors/readers for more resources
The antibody-based targeted delivery of bioactive agents to sites of angiogenesis is an attractive therapeutic strategy for cancer treatment, but is largely unexplored for chronic inflammatory diseases. In this article, we show hat the extra domain B (EDB) domain of fibronectin, a marker of angiogenesis, is expressed in psoriatic lesions, and that the anti-EDB human antibody L19 can selectively localize to chronically inflamed skin in vivo. The LA-based delivery of the cytokines IL10 and IL12 did not improve or worsen inflammation in a mouse model of chronic skin inflammation, which overexpressed vascular enclothelial growth factor under the control of the keratin-14 promoter. By contrast, the L19-based targeted delivery of the proinflammatory cytokine IL2 or of the photosensitizer Sn(IV) chlorin e6 resulted in an increased swelling and reddening of inflamed skin. These results indicate that antibodies specific to components of the modified extracellular matrix can selectively accumulate at chronically inflamed sites in vivo. This observation now stimulates the search for bioactive moleciles which can be fused to antibodies and which may confer a therapeutic benefit as a result of their preferential accumulation in psoriatic lesions and other sites of inflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available